Cutaneous lymphoma in Japan, 2012–2017: A nationwide study

Fujii, Kazuyasu; Hamada, Takeshi; Shimauchi, Takatoshi; Asai, Jun; Fujisawa, Yasuhiro; Ihn, Hironobu; Katoh, Norito

doi:10.1016/j.jdermsci.2020.01.010

Cited by 22 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bexarotene has been available in Japan since June 2016, which is recommended as one of the key drugs for the treatment of patients with relapsed/refractory early and advanced stage cutaneous T‐cell lymphoma (CTCL) around the world 1–5 . Mycosis fungoides (MF) is the most common type of CTCL 6–10 . In the advanced stage, differences in first‐line therapeutic approaches can be seen between nations and/or geographical regions 11 …”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: Real‐world experience from post‐marketing surveillance

Hamada

Morita

Suga

et al. 2021

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

To establish real‐world evidence about the safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma, we conducted a nationwide cohort study using data from post‐marketing surveillance for bexarotene treatment. In total, 294 patients with cutaneous T‐cell lymphoma were identified between June 2016 and June 2018. Of these, 267 patients were included as the safety analysis set. Of the 267 patients, 175 were included in the efficacy analysis set. Of these, 139 patients had mycosis fungoides, including 46 with early stage disease and 93 with advanced stage disease. Among the 139 patients with mycosis fungoides, the objective response rate was 46.8%. A significant difference in objective response rate was detected between patients who started with bexarotene at 300 mg/m2 (61.6%) and patients who started with bexarotene at less than 300 mg/m2 (22.6%, p < 0.001). Of the 139 patients with mycosis fungoides, 92 were treated with a combination of bexarotene plus photo(chemo)therapy. A significant difference in objective response rate was seen between bexarotene with a combination of photo(chemo)therapy (57.6%) and bexarotene without a combination of photo(chemo)therapy (25.5%, p < 0.001). Starting bexarotene at 300 mg/m2 and combination with photo(chemo)therapy were detected as independent factors influencing response. Common treatment‐related adverse events included hypothyroidism (85.8%), hypertriglyceridemia (68.5%), hypercholesterolemia (43.8%), and neutropenia (21.3%). Hypertriglyceridemia, hypercholesterolemia, and neutropenia occurred more frequently in patients who started with bexarotene at 300 mg/m2 than patients who started with bexarotene at less than 300 mg/m2 (hypertriglyceridemia, 76.4% vs. 57.0%, p = 0.001; hypercholesterolemia, 49.0% vs. 36.4%, p = 0.045; neutropenia, 28.0% vs. 12.1%, p = 0.002; respectively). The present study indicates that starting bexarotene at 300 mg/m2 and combination of photo(chemo)therapy offer a promising efficacy for the treatment of patients with mycosis fungoides. Efficacy of low‐dose bexarotene plus photo(chemo)therapy should be evaluated in future.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: Real‐world experience from post‐marketing surveillance

Hamada

Morita

Suga

et al. 2021

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among various subtypes of cutaneous lymphomas, MF is the most common form, covering about half of all cutaneous lymphomas [5]. Skin lesions seen in MF patients are erythematous patches, plaques, or tumors.…”

Section: Classification Of Cutaneous Lymphomasmentioning

confidence: 99%

Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas

Sugaya

2021

IJMS

View full text Add to dashboard Cite

Primary cutaneous lymphomas are heterogenous lymphoproliferative disorders. Some patients show rapid progression and the need for treatment of advanced disease is still unmet. The frequency of each subtype of cutaneous lymphoma varies among different ethnic groups, as do the medical systems found in different countries. It is important to know the differences in clinical guidelines in different areas of the world. Although current monochemotherapy with gemcitabine or pegylated liposomal doxorubicin is temporarily effective for mycosis funogides (MF) and Sézary syndrome (SS)—representative types of cutaneous lymphomas—the duration of response is usually limited. Therefore, treatment strategies targeting tumor-specific molecules have been developed. Molecular targets for MS/SS are currently CD30, CCR4, CD25, CD52, and histone deacetylases, most of which are surface molecules specifically expressed on tumor cells. As a result of advances in research techniques, different kinds of genomic alterations in MF/SS have been revealed. Molecular targets for MS/SS in the near future would be CD158k, JAK, PIK3, the mammalian target of rapamycin, and microRNAs, most of which mediate intracellular signaling pathways. Personalized therapy based on the detection of the genetic signatures of tumors and inhibition of the most suitable target molecules constitutes a future treatment strategy for MF/SS.

show abstract

“…Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphomas (CTCLs), a heterogenous group of non-Hodgkin lymphoma of T-cell origin that is defined to primarily present in the skin, representing almost 50% of all CTCL cases [ 1 , 2 ]. MF is characterized by malignant proliferation of CD4 + T cells with epidermotropism in the skin and generally has a prolonged clinical course.…”

Section: Introductionmentioning

confidence: 99%

“…A part, but not all, of such patients progress to develop skin tumors, with subsequent lymph node and rarely visceral organ involvement and they are regarded as having advanced-stage disease [ 1 , 3 , 4 , 5 , 6 ]. Guidelines describing the diagnosis of MF are created by various professional societies [ 2 , 7 , 8 , 9 ], and the methods for diagnosis are mostly consistent in those guidelines. Generally, the diagnosis of MF is made comprehensively based on clinical presentation, clinical course, pathological and immunohistochemical analysis, and occasionally molecular biological analysis.…”

Section: Introductionmentioning

confidence: 99%

Diagnosis of Early Mycosis Fungoides

Miyagaki¹

2021

Diagnostics

View full text Add to dashboard Cite

Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphomas, generally has a favorable clinical course. Early MF typically presents erythematous patches and/or plaques and lasts for many years without affecting the life expectancy. Only limited cases progress to develop skin tumors, with subsequent lymph nodes and rarely visceral organ involvement. One of the clinical problems in early MF is the difficulty in differentiating the disease from benign inflammatory disorders (BIDs), such as atopic dermatitis, chronic eczema, and psoriasis. In some MF cases, clinical and pathological findings are similar to those of BIDs. However, the accurate diagnosis of early MF is quite important, as inappropriate treatment including immunosuppressants can cause unfavorable or even fatal outcomes. This article focuses on general methods and novel tools for diagnosis of early MF.

show abstract

Cutaneous lymphoma in Japan, 2012–2017: A nationwide study

Cited by 22 publications

References 29 publications

Safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: Real‐world experience from post‐marketing surveillance

Safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: Real‐world experience from post‐marketing surveillance

Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas

Diagnosis of Early Mycosis Fungoides

Contact Info

Product

Resources

About